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mycin resistance, which is markedly higher than the 3%
(only six out of 200 strains collected between 1992 and 1996)
reported recently by Reinert et al [3] for Germany, and re£ects
the trend reported by Kresken et al [4] who observed an
increase in erythromycin resistance (break-point r1mg/L,
which is lower than the one used in the Alexander Project [2])
from 3.6% in 1992 to 11.3% in 1997. Frankfurt (if not Ger-
many) seems to have joined the c`lub of countries with penicil-
lin-resistant pneumococci'.
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Localized Mycobacterium avium complex infection in a
patient on HAART
The increases in CD4 T-lymphocytes count induced by anti-
retroviral therapy provide an anti-infective protection such
that primary prophylaxis against opportunistic infections can
be stopped. There is, however, concern that CD4 count aug-
mented by drug therapy may not include cells speci¢cally
active against some of the frequent opportunistic infections,
including atypical mycobacterial infections [1].
We report a case ofMycobacterium avium intracellulare occur-
ing in a 55-year-old retired bank manager who had been
unwell for about 9 months with repeated respiratory chest
infections and loss of weight. He was thought initially to have
an underlying neoplasm and had undergone extensive investi-
gations including a whole body CT (computed axial tomo-
graphic) scan at the referring hospital. He was divorced in 1978
and during the 1980s had multiple homosexual contacts. Dur-
ing the 2weeks prior to being referred he had become progres-
sively short of breath associated with a dry cough. Physical
examination was essentially normal apart from a temperature
of 37.5 C. His chest X-ray revealed bulky hilar lymphadeno-
pathy and there were patchy opacities of both the mid-zones.
Blood gas analysis revealed pO2 10.6 kPa (4.5^6.1) and pCO2
4.1kPa (12.0^14.0). Pulmonary function tests showed that the
TLCO was 6.77mmol/min/kPa (62% of expected) and kCO
was 1.18mmol/min/kPa/L (84% of expected). Although
induced sputums taken for indirect immuno£uorescent anti-
body stain against Pneumocystis carini were negative, a subse-
quent broncho-alveolar lavage examination was strongly
positive. Acid-fast bacilli were not demonstrated. He was
commenced on high dose cotrimoxazole (120mg/kg per day)
with prednisolone. He was counselled and consented to be
tested for HIV and this was shown to be positive (ELISA
Abbot (Abbot Laboratories, Chicago, USA); ELISAOrganon
(OrganonTeknika Ltd, Boxtel, the Netherlands) and INNO-
LIA Blot test (Ghent, Belgium)). The HIV load was noted to
Table 2 Breakpoints, R I S distribution, geom. mean and range of 97 pneumococcal strains
Drug name Breakpoints No. of strains %R %I %S MIC50 MIC90 Geom Mean Range
PEN S0.006; R2 97 4.1 9.3 86.6 0.023 0.125 0.03 0.00±2
ERY S0.0.5; R4 97 14.4 1.0 84.5 0.125 512 0.38 0.047±512
DOXY S0.2; R8 97 15.5 1.0 83.5 0.5 16 0.64 0.064±64
CLIN S0.0.5; R4 97 13.4 0 86.6 0.125 512 0.32 0.016±512
MOX S0.1; R4 97 0 0 100 0.19 0.25 0.20 0.094±0.38
LEV S0.2; R8 97 0 8 92 1 1.5 1.12 0.25±3
PEN, Penicillin G; ERY, erythromycin; DOXY, doxycyclin; CLIN, clindamycin; MOX, moxi¯oxacin; LEV, levo¯oxacin.
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be 750 000 copies/mL (Roche Amplicor) with the CD4
count of 63 cells/uL (600^1100). He symptomatically
improved with treatment but became very confused and dis-
orientd on completion of the therapy for PCP, and a CTscan
of the brain revealed a generalized cerebral atrophy. A lumbar
puncture showed the protein elevated at 1.44 g/L (0.18^0.5)
but there were no cells or organisms seen and the cryptococcal
antigen (Latex agglutination test) was negative. He was com-
menced on anti-retroviral therapy of zidovudine, lamividine
and indinavir. He was discharged home but had an episode of
mania requiring treatment with haloperidol and lorezapam
with good response.
He clinically improved but 2 months later he developed a
dry, unproductive cough with sweats and a fever. He was
noted to be anemic with the hemoglobin of 9.9 (13.5^18.0 g/
dL). A repeat chest X-ray showed a nodular opacity at the apex
of the right lower lobe. A CT scan of the thorax (Figure1)
demonstrated mediastinal lymphadenopathy and a patchy area
of con£uent nodular opaci¢cation with a cavity in the apical
segment of the right lower lobe. Broncho-alveolar £uid
examination showed presence of acid-fast bacilli by Ziel^
Neilsen stain, and a trans-bronchial biopsy of the lesion
showed granulomatous in£ammation with central necrosis
containing polymorphs. Subsequent culture (MB\BacT
OrganonTeknika Ltd) of the lavage £uid grewM. avium com-
plex.Three sets of blood cultures did not show any growth. At
this stage the HIVviral load was reduced signi¢cantly to 1850
copies/mLwith a CD4 count of 250 cells/uL.The polymerase
chain reaction (PCR) for M. tuberculosis was negative. The
patient was commenced on treatment with azithromycin and
rifabutin. The organism was multiresistant to isoniazid,
ethambutol, rifampicin, pyrazinamide, cipro£oxacin, azi-
thromycin and streptomycin (resistance ratio method). His
symptoms resolved and hewas discharged home.
Our case demonstrates the ever increasing spectrumof clin-
ical manifestations associated with opportunistic infections in
HIV-infected individuals in the era of HAART (Highly
Active AntiRetroviral Therapy). Initiation of combination
anti-retroviral therapy results in the dramatic decrease of the
HIV viral load with a concomitant restoration of cell-
mediated immune function [1].This enhanced immunity may
lead to a marked in£ammatory reaction and to altered clinical
manifestations of pre-existing latent infections. A recent
study reported the incidence of pathogen-associated in£am-
matory diseases occuring in 143 HIV-infected patients after
treatment with potent anti-retroviral therapy. Thirty-three
responders (25%) had one or more episodes of opportunistic
infections. Five had localized MAC disease, six had exacerba-
tion of CMV retinitis, nine had mucocutaneous herpes, eight
had dermatomal zoster, four had myelitis and/or encephalitis
with presumptive HSV infection, three had HCV-associated
hepatitis, two had MTB-associated lymphadenitis/pneumo-
nitis or cerebritis and six had in£amed molluscum contagio-
sum or warts.These diseases occured during the ¢rst 2months
of therapy and a low baseline CD4 T-cell count was the only
predictor of their onset [2].
There have been a number of reports of a clinical syndrome
of MAC-related in£ammatory lymphadenitis on initiating
Figure 1 CT scan demonstrating the localized cavitation of the lung due to Mycobacterium avium complex.
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HAART. Race et al recognized this on initiation of a protease
inhibitor, indinavir, in patients with advanced HIV-1 disease
[3]. A retrospective studyconducted on 52 patientswithmyco-
bacterial lymphadenitis in HIV showed 12 patients developed
the infection within 12weeks of initiating combination anti-
retroviral therapy. The clinical presentation, which may vary,
was in these cases of localized disease andwas associatedwith a
relatively high CD4 count. All patients showed a good immu-
nological and virological response toHAART [4].
A further analysis identi¢ed ¢ve patients who developed
mycobacterial lymphadenitis within 8weeks of initiating
HAART. All patients had fever, weakness and splenomegaly.
Four of the ¢ve patients were anemic with Hb<10 g/dL and
demonstrated lymphadenopathy. This was cervical in three,
submandibular in two, mediastinal in three and preauricular
in one [5]. Interestingly, our patient presented with a primary
lung lesion (Figure 1).We are not aware of any other literature
describing cavitatory lung lesions, due to localized MAC
infection, relating to HAART therapy inHIVinfection.
MAC infections may re£ect restoration of pathogen-speci-
¢c immune responses rather than reactivation of the initiating
infection. Partial immune reconstitution, as demonstrated by
an increase in the CD4 counts on anti-retroviral therapy is
likely to be responsible for the localized MAC infection.This
reconstitution may lead to an unmasking of subclinical infec-
tion and an enhanced immune response to mycobacterial anti-
gens. There is evidence to show that immune reconstitution
due to HAARToccurs in two stages and the initial CD4 lym-
phocyte proliferation is primarly of the memory subsets [6^8].
Thus this marked memoryT-cell-mediated and antigen-spe-
ci¢c in£ammatory reaction may then lead to tissue suppura-
tion and granuloma formation, the hallmarks of
mycobacterial disease.
The occurence and severity of illness in our patient with
localized but untreated MAC infection after the start of
HAART suggests that patients with advanced HIV disease
should be assessed for active mycobacterial infection before
the initiation of such therapy. It is also important to consider
that dual opportunistic infections may occur in advanced dis-
ease as our patient demonstrated. Therefore, patients with
severe immune dysfunction should be monitored very care-
fully, in particular during the ¢rst weeks after initiating of
HAART. Indeed, it may be important in the ¢rst few months
of HAART to maintain patients on prophylaxis for opportu-
nistic infections.
H.Thakerand E. L.C.Ong
Department of Infection&TropicalMedicine,
University of NewcastleMedical School,
Newcastle General Hospital,
Newcastle uponTyneNE4 6BEUK
E-mail: e.l.c.ong@ncl.ac.uk
R E F ER E N C ES
1. Ong ELC. Prophylaxis against disseminated Mycobacterium avium
complex in AIDS. J Infect1999; 38: 6^8.
2. FrenchM, Lenzo N, JohnM,Mallal S, Price P, Flexman J. Immune
restoration disease after treatment of immunode¢cient HIV-
infected patients with potent anti-retroviral therapy [Abstract 340/
22323]. IntConfAIDS, 1998;12: 327^8.
3. Race EM,Adelson-Mitty J et al. Focal mycobacterial lymphadenitis
following initiation of protease- inhibitor therpy in patients with
advanced HIV-1disease. Lancet1998; 351: 252^5.
4. Phillips P, Kwiatkowski MB, Copland M, Craib K, Montaner J.
Mycobacterial lymphadenitis associatedwith the initiation of com-
bination antiretroviral therapy. JAcquir ImmuneDe¢c SyndrHumRet-
rovirol1999; 20(2): 122^8.
5. Ho¡mann C, Horst HA, Degen O,Van Lunzen J, Stellbrink HJ.
Manifestation of mycobacterial infection after initiating of highly
active antiretroviral therapy (HAART) [Abstract 22172]. Int Conf
AIDS1998;12: 296.
6. Pontesilli O, Kerkhof-Garde. S et al. Functional lymphocyte recon-
stitution and HIV-1 speci¢c T-cell responses during highly active
antiretroviral therapy (HAART) [Abstract 31134]. Int Conf AIDS
1998;12: 113.
7. Mezzaroma E, Pinter G, Cunsolo L et al. Lymphocyte subsets and
functional changes in HIV-1 infected patient during HAART
[Abstract12302]. IntConfAIDS1998;12.
8. Oliver Lantz F, Martinon I, Peguillet A et al. Longitudinal analysis
of the immune reconstitution after HAART initiation in pre-
viously untreated patients [Abstract 21123]. Int Conf AIDS 1998;
12.
Endocarditis due to Gemella haemolysans in a patient with
hemochromatosis
Gemella haemolysans is a facultative anaerobic Gram-positive
coccus that can be a commensal of the upper respiratory tract
and oral cavity of humans.The clinical spectrum of infections
produced by this microorganism includes endocarditis, septi-
cemia and meningitis.We report a case of endocarditis due to
G. haemolysans in a patients with hemochromatosis.
A 77-year-old manwith a long history of hemochromatosis
with chronic liver disease and arterial hypertension was
admitted to hospital because of malaise, anorexia, weight loss
and progressive dyspnea over the previous 4months. On
admission he was afebrile and the physical examination
revealed a grade 2 diastolic ejection murmur in the left sternal
border and hepatomegaly. Laboratory studies disclosed the
following data: leukocyte count 12 000/mm3 (80% neutro-
phils, 17% lymphocytes), hematocrit 48%, erythrocyte sedi-
mentation rate of 54mm/h, iron 200 mg/dL, ferritin 2277U
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